Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection

ClinicalTrials.gov ID: NCT00047814

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00047814. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 12:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multiple Rising-Dose Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of 4 weeks therapy with FK788 in subjects with chronic hepatitis C virus (HCV) infection. Also, to assess the effect of FK788 on serum ALT concentration and hepatitis C viral level during therapy and for four weeks following therapy.

Study identification

NCT ID
NCT00047814
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Astellas Pharma Inc
Industry
Enrollment
48 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 60 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 2002 (Type not available)
Primary completion
Not listed
Completion
Mar 2006 (Actual)
Last update posted
Dec 9, 2011

2002 – 2006

United States locations

U.S. sites
9
U.S. states
8
U.S. cities
9
Facility City State ZIP Site status
Liver Center Huntington Memorial Hospital Pasadena California 91105 —
Rocky Mount Gastroenterology Lakewood Colorado 80215 —
University of Florida and Shands Hospital Gainsville Florida 32610 —
Liver Center BIDMC - Harvard Boston Massachusetts 02215 —
Gastroenterology and Hepatology Kansas City Missouri 64131 —
Carolinas Center for Liver Disease Charlotte North Carolina 28203 —
Duke University Durham North Carolina 27705 —
Thomas Jefferson University, Gastroenterology and Hepatology Philadelphia Pennsylvania 19107 —
Northwest Medical Specialties, PLLC Infections Limited, P.S. Tacoma Washington 98405 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00047814, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 9, 2011 · Synced Nov 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.